Clinical Trials · NCT05720260
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- National Taiwan University Hospital
- Enrollment
- 42
- Start date
- Jan 2023
- Locations
- 1 site, Taiwan
- Primary endpoint
- Progression-free survival